Innate Pharma S.A. (IPHA) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Innate Pharma S.A. (IPHA) over the past year, losing 7.5% versus a loss of 22.1%. Over five years, IPHA leads with a -74.1% price change compared with -98.3% for YARW. Yarrow Bioscience is the larger company by market cap ($174.7 million vs $169.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | YARW |
|---|---|---|
| Share price | $1.52 | $18.78 |
| Market cap | $169.78M | $174.69M |
| 1-day change | -4.40% | +0.24% |
| YTD return | -13.14% | -35.26% |
| 1-year return | -22.05% | -7.51% |
| 5-year return | -74.11% | -98.29% |
| EPS (TTM) | $-0.59 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $46.95 |
| 52-week low | $1.17 | $16.05 |
| Distance from 52-week high | -43.91% | -60.01% |
| Analyst consensus | none | none |
| Avg. price target upside | +338.82% | +203.60% |
| Average volume | 158.98K | 86.67K |
| Shares outstanding | 111.70M | 9.30M |
| Employees | 120 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed IPHA by 14.5 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
IPHA vs YARW FAQ
Which is bigger, Innate Pharma S.A. or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $174.69M compared with $169.78M for Innate Pharma S.A. (IPHA).
Which stock has performed better over the past year, IPHA or YARW?
YARW returned -7.51% over the past 12 months, compared with -22.05% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Yarrow Bioscience in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Innate Pharma S.A. and Biotechnology: Pharmaceutical Preparations for Yarrow Bioscience.